Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies
Abstract
Introduction: Different observational studies have analyzed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on the risk of ocular adverse events (AEs). The present meta-analysis aimed to assess the effects of GLP-1 RAs on the risk of ocular AEs, including retinopathy, glaucoma, and non-arteritic anterior ischemic optic neuropathy (NAION).
Methods: A systematic review and meta-analysis of observational studies was conducted in PubMed, Embase, and Web of Science from 2006 to 2025. Studies involving individuals diagnosed with diabetes and/or obesity and overweight, receiving GLP-1 RAs, and evaluating outcomes related to ocular AEs were included. A random-effect meta-analysis approach was used. This study followed the PRISMA statement.
Results: A total of 28 observational studies (6 for semaglutide and 22 for all GLP-1 RAs) involving T2DM patients were included. When compared to other antidiabetic treatments, GLP-1 RAs did not increase the risk of developing ocular disorders such as NAION (RR, 1.01; 95% CI, 0.62-1.64; I2, 89%), glaucoma (HR, 0.84; 95% CI, 0.71-1.00; I2, 91%), and retinopathy (new onset or progression) [(HR, 0.96; 95% CI, 0.85-1.08; I2, 91%) (HR, 0.97; 95% CI, 0.83-1.14; I2, 65%)].
Conclusion: Even if no difference was observed between GLP-1 RAs and other antidiabetic medications for all safety outcomes evaluated, it is optimal to monitor the administration of these molecules.
Systematic review registration:…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.